1993Journal of Antimicrobial ChemotherapyRequires access

Selection of variants of the TEM-1 β lactamase, encoded by a plasmid of clinical origin, with increased resistance to β-lactamase inhibitors

C. J. Thomson, S. G. B. Amyes

Open publisher page 16 citations

Abstract

A TEM-1 derived variant beta-lactamase with increased resistance to beta-lactamase inhibitors was selected in vitro. The variant beta-lactamase was obtained from the parent strain Escherichia coli J62-2 containing resistance plasmid R1 which encodes the TEM-1 beta-lactamase. The variants were obtained by repeated subculture of E. coli J62-2 (R1) for five days in the presence of sub-inhibitory concentrations of amoxycillin plus clavulanic acid. Comparison of this variant beta-lactamase with a clinically isolated TEM derived beta-lactamase, with increased resistance to beta-lactamase inhibitors, suggests that they are the same enzyme. Both beta-lactamases have the same pI at 5.25 and have similar ID50 values for the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam.

About this research paper

What this paper is about

A TEM-1 derived variant beta-lactamase with increased resistance to beta-lactamase inhibitors was selected in vitro. The variant beta-lactamase was obtained from the parent strain Escherichia coli J62-2 containing resistance plasmid R1 which encodes the TEM-1 beta-lactamase. The variants were obtained by repeated subculture of E. coli J62-2 (R1) for five days in the presence of sub-inhibitory concentrations of amoxycillin plus clavulanic acid. Comparison of this variant beta-lactamase with a clinically isolated TEM derived beta-lactamase, with increased resistance to beta-lactamase inhibitors, suggests that they are the same enzyme. Both beta-lactamases have the same pI at 5.25 and have similar ID50 values for the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam.

Why it matters

OpenAlex reports 16 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A TEM-1 derived variant beta-lactamase with increased resistance to beta-lactamase inhibitors was selected in vitro. The variant beta-lactamase was obtained from the parent strain Escherichia coli J62-2 containing resistance plasmid R1 which encodes the TEM-1 beta-lactamase. The variants were obtained by repeated subculture of E. coli J62-2 (R1) for five days in the presence of sub-inhibitory concentrations of amoxycillin plus clavulanic acid. Comparison of this variant beta-lactamase with a clinically isolated TEM derived beta-lactamase, with increased resistance to beta-lactamase inhibitors, suggests that they are the same enzyme. Both beta-lactamases have the same pI at 5.25 and have similar ID50 values for the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam.

Key concepts: Clavulanic acid, Beta-lactamase, Sulbactam, Beta-Lactamase Inhibitors, Microbiology, Escherichia coli, Plasmid, Tazobactam

Related papers

Back to paper searchBrowse research topicsOriginal source
Selection of variants of the TEM-1 β lactamase, encoded by a plasmid of clinical origin, with increased resistance to β-lactamase inhibitors — Research Paper | ScholarLens